| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 1.96 MB | Adobe PDF |
Advisor(s)
Abstract(s)
: Many graphene-based materials (GBNs) applied to therapy and diagnostics (theranostics)
in cancer have been developed. Most of them are hybrid combinations of graphene with other
components (e.g., drugs or other bioactives, polymers, and nanoparticles) aiming toward a synergic
theranostic effect. However, the role of graphene in each of these hybrids is sometimes not clear
enough and the synergic graphene effect is not proven. The objective of this review is to elaborate on
the role of GBNs in the studies evaluated and to compare the nanoformulations in terms of some of
their characteristics, such as therapeutic outcomes and toxicity, which are essential features for their
potential use as bionanosystems. A systematic review was carried out using the following databases:
PubMed, Scopus, and ISI Web of Science (2013–2018). Additional studies were identified manually by
consulting the references list of relevant reviews. Only English papers presenting at least one strategy
for cancer therapy and one strategy for cancer diagnostics, and that clearly show the role of graphene
in theranostics, were included. Data extraction and quality assessment was made by reviewer
pairings. Fifty-five studies met the inclusion criteria, but they were too heterogeneous to combine in
statistical meta-analysis. Critical analysis and discussion of the selected papers are presented.
Description
Keywords
Systematic review Graphene-based materials Graphene oxide Reduced graphene oxide Nano-graphene Graphene quantum dots Theranostics Cancer
